Items where Author is "Kanavos, Panos"

Number of items: 227.
  • Assessing the value of provider-facing digital health technologies used in chronic disease management::toward a value framework based on multistakeholder perceptions. (2024) Main, Caitlin and Haig, Madeleine and Chávez, Danitza and Kanavos, Panos picture_as_pdf
  • Impact of Managed Entry Agreements on availability of and timely access to medicines:an ex-post evaluation of agreements implemented for oncology therapies in four countries. (2022) Efthymiadou, Olina and Kanavos, Panos picture_as_pdf
  • Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe:a costing and health-related quality of life study. (2022) Angelis, A. and Mellerio, J. E. and Kanavos, Panos picture_as_pdf
  • The future of oncology policy. (2022) Gill, Jennifer L and Mills, Mackenzie J and Wharton, George A and Kanavos, Panos picture_as_pdf
  • Challenges for health systems seeking to embrace virtual health care for population health. (2022) Kanavos, Panos and Vogelsang, Michelle and Haig, Madeleine and Kolovou, Vasiliki picture_as_pdf
  • Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. (2022) Michaeli, Daniel Tobias and Mills, Mackenzie and Kanavos, Panos picture_as_pdf
  • Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. (2022) Michaeli, Daniel Tobias and Mills, Mackenzie and Michaeli, Thomas and Miracolo, Aurelio and Kanavos, Panos picture_as_pdf
  • Similarities and differences in Health Technology Assessment systems and implications for coverage decisions:evidence from 32 countries. (2022) Fontrier, Anna-Maria and Visintin, Erica and Kanavos, Panos picture_as_pdf
  • Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. (2021) Kamphuis, Bregtje W. and Kanavos, Panos picture_as_pdf
  • Health related quality of life aspects not captured by EQ-5D-5L: results from an international survey of patients. (2018) Efthymiadou, Olina and Mossman, Jean and Kanavos, Panos picture_as_pdf
  • Differentiation of health related quality of life outcomes between five disease areas; results from an international survey of patients. (2018) Efthymiadou, Olina and Mossman, Jean and Kanavos, Panos picture_as_pdf
  • Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. (2018) Angelis, Aris and Lange, Ansgar and Kanavos, Panos
  • The 30-billion-dollar distribution markups and taxes of pharmaceuticals in Latin American countries:impact, options, and trade-offs. Leon, Giovanny and Gonzalez-Pier, Eduardo and Kanavos, Panos and Ruiz de Castilla, Eva Maria and Machinicki, Gerardo picture_as_pdf
  • Access to medicines in Europe delays and challenges for patient access:delays and challenges for patient access. Kamphuis, Bregtje and Fontrier, Anna-Maria and Gill, Jennifer and Efthymiadou, Olina and Salyga, Hana and Kanavos, Panos
  • Access to personalised oncology in Europe. Gill, Jennifer and Fontrier, Anna-Maria and Miracolo, Aurelio and Kanavos, Panos
  • Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Kanavos, Panos and Angelis, Aris
  • Availability and affordability of medicines and assessment of quality systems for prescription of medicines in the Republic of Moldova: final report. Sautenkova, Nina and Ferrario, Alessandra and Bolokhovets, Ganna and Kanavos, Panos
  • Availability of medical supplies during the 2010 Pakistan floods. Tordrup, David and Ahmed, Waqas and Bukhari, Khalid Saeed and Kanavos, Panos
  • Availability of medicines in Estonia: an analysis of existing barriers and options to address them. Ferrario, Alessandra and Reinap, Marge and Pedersen, Hanne Bak and Kanavos, Panos
  • Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Kanavos, Panos and Vandoros, Sotiris and Garcia-Gonzalez, Pat
  • Can economic evaluation guidelines improve efficiency in resource allocation? Kanavos, Panos and Trueman, P and Bosilevac, A
  • Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público. Helfer, Ana Paula and Camargo, Aline Lins and Tavares, Noemia Urruth Leão and Kanavos, Panos and Bertoldi, Andréa Dâmaso
  • Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Morgan, S and McMahon, M and Mitton, C and Rougehead, E and Kirk, R and Kanavos, Panos and Menom, D
  • Challenges and opportunities in improving access to medicines through efficient public procurement in WHO European Region. Ferrario, Alessandra and Kanavos, Panos and Humbert, Tifenn and Iwamoto, Kotoji and Bak Pedersen, Hanne
  • Changing the treatment paradigm in multiple sclerosis: are the attitudes of patients and physicians aligned? Mossman, Jean and Kanavos, Panos and Tinelli, Michela
  • Clinical, ethical, and socioeconomic considerations for prescription drug use during pregnancy in women suffering from chronic diseases. Tzouma, Victoria and Grepstad, Mari and Grimaccia, Federico and Kanavos, Panos
  • Colocteral cancer management and prevention policies in Greece. Geitona, Mary and Kanavos, Panos
  • Colorectal cancer in Europe and Australia: challenges and opportunities for the future. Kanavos, Panos and Schurer, Willemien and Owusu-Apenten, Candida and Sullivan, Richard
  • Colorectal cancer management in the United Kingdom: current practice and challenges. Schurer, Willemien and Kanavos, Panos
  • Comment on: “Does MCDA trump CEA?”. Angelis, Aris and Kanavos, Panos picture_as_pdf
  • Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Nicod, Elena and Kanavos, Panos
  • Comparing generic drug markets in Europe and the United States:prices, volumes, and spending. Wouters, Olivier J. and Kanavos, Panos and McKee, Martin
  • Competition in off-patent drug markets: issues, regulation and evidence. Kanavos, Panos and Costa-i-Font, Joan and Seeley, Elizabeth
  • Competition in prescription drug markets: is parallel trade the answer? Kanavos, Panos and Vandoros, Sotiris
  • Competition issues in the distribution of pharmaceuticals. Kanavos, Panos and Wouters, Olivier J.
  • Concurrence dans la distribution de produits pharmaceutiques. Kanavos, Panos and Wouters, Olivier J.
  • Controlling expenditure within the Spanish pharmaceutical market: macro- and micro-level policy approaches. Kanavos, Panos and Mills, Mackenzie and Cheatley, Jane and Lopez-Casasnovas, Guillem and Manganelli, Anton and Maynou, Laia and Serra, Miquel
  • Cost and impact of non-treating severe mental illnesses (SMIs): the case study of schizophrenia. Tinelli, Michela and Kanavos, Panos
  • Cost, outcomes, treatment pathways and challenges for diabetes care in Italy. Grimaccia, Federico and Kanavos, Panos
  • Critique of the American Society of Clinical Oncology value assessment framework for cancer treatments: putting methodologic robustness first. Angelis, Aris and Kanavos, Panos
  • Cross-border issues in the provision of health services: are we moving towards a European health policy? Kanavos, Panos and McKee, Martin
  • Cross-border patient flows for health care in Europe: A feasibility study. Exworthy, M. and Kanavos, Panos
  • Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Ferrario, Alessandra and Kanavos, Panos picture_as_pdf
  • Delphi approach to select rare diseases for a European representative survey: the BURQOL-RD study. Linertová, Renata and Serrano-Aguilar, Pedro and Posada-de-la-Paz, Manuel and Hens-Pérez, Manuel and Kanavos, Panos and Taruscio, Domenica and Schieppati, Arrigo and Stefanov, Rumen and Péntek, Márta and Delgado, Claudia and Graf von der Schulenburg, Johann-Matthias and Persson, Ulf and Chevreul, Karine and Fattore, Giovanni and Worbes-Cerezo, Melany and Sefton, Mark and López-Bastida, Julio
  • Determinants of branded prescription medicine prices in OECD countries. Kanavos, Panos and Vandoros, Sotiris
  • Determinants of managed entry agreements in the context of Health Technology Assessment:a comparative analysis of oncology therapies in four countries. Efthymiadou, Olina and Kanavos, Panos picture_as_pdf
  • Determinants of out-of-pocket pharmaceutical expenditure and access to drugs in Catalonia. Costa-i-Font, Joan and Kanavos, Panos and Rovira-Forns, Joan
  • Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: a mixed methods study. Nicod, Elena and Kanavos, Panos
  • Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. Kamphuis, Bregtje and Fontrier, Anna-Maria and Haig, Madeleine and Politopoulou, Konstantina and Salyga, Hana and Gentilini, Arianna and Kanavos, Panos picture_as_pdf
  • Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. Nicod, Elena and Jackson, Timothy L. and Grimaccia, Federico and Angelis, Aris and Costen, Marc and Haynes, Richard and Hughes, Edward and Pringle, Edward and Zambarakji, Hadi and Kanavos, Panos
  • Do generics offer significant savings to the UK National Health Service? Current Medical Research and Opinion, vol. 23(1). Kanavos, Panos
  • Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Mills, Mackenzie and Kanavos, Panos
  • Do reimbursement recommendations by the Canadian Agency for Drugs and Technology in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario? Fontrier, Anna-Maria and Kanavos, Panos picture_as_pdf
  • Does external reference pricing deliver what it promises? Evidence on its impact at national level. Kanavos, Panos picture_as_pdf
  • Does the work of the National Institute for Health and Clinical Excellence (NICE) have any relevance for the United States? Sorenson, Corinna and Drummond, Michael and Kanavos, Panos and McGuire, Alistair
  • Drivers and methodological considerations associated with the acceptability of real-world evidence for effectiveness/efficacy by regulators and HTAs:evidence from North America, Europe, and Australia. Candore, Gianmario and Martin, Claire and Gabarro, Montse Soriano and Mills, Mackenzie and Kanavos, Panos and Bromley, Susan and Cooper, Amy L. and Wolf, Birgit and Bolot, Paul and Franklin, Joe and Wasem, Jurgen and Schneeweiss, Sebastian and Sculpher, Mark and Civitelli, Diego and Chavez-Montoya, Danitza
  • Drugs US: are prices too high?: measuring international pharmaceutical price differences. Kanavos, Panos and Vandoros, Sotiris
  • EU pharmaceutical policy: the challenges and opportunities of enlargement. Kanavos, Panos
  • An EU-wide approach to HTA:an irrelevant development or an opportunity not to be missed? Kanavos, Panos and Angelis, Aris and Drummond, Michael
  • Early chronic kidney disease: diagnosis, management and models of care. Wouters, Olivier J. and O'Donoghue, Donal J. and Ritchie, James and Kanavos, Panos and Narva, Andrew S.
  • Early health technology assessment during nonalcoholic steatohepatitis drug development:a two-round, cross-country, multicriteria decision analysis. Angelis, Aris and Thursz, Mark and Ratziu, Vlad and O'Brien, Alistair and Serfaty, Lawrence and Canbay, Ali and Schiefke, Ingolf and Bana e Costa, João C. and Lecomte, Pascal and Kanavos, Panos picture_as_pdf
  • Economic evaluation for orphan drugs: is it possible? Kanavos, Panos and Saka, R
  • Economic issues in access to medications: Schizophrenia treatment in England. Knapp, Martin and Kanavos, Panos and King, Derek and Yesudian, Hannah Monica
  • Efectos del comercio paralelo de medicamentos en la Unión Europea y evidencia de Alemania. Costa-i-Font, Joan and Kanavos, Panos
  • Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: a population-based study. Park, Sylvia and Ross-Degnan, Dennis and Adams, Alyce S and Sabin, James and Kanavos, Panos and Soumerai, Stephen B
  • Encouraging the use of generic medicines: implications for transition economies. King, Derek R. and Kanavos, Panos
  • Ensuring value for money in health care: The role of HTA in the European Union. Sorenson, Corinna and Drummond, Michael and Kanavos, Panos
  • Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review. Bertoldi, Andréa D. and Kanavos, Panos and França, Giovanny V. A. and Carraro, André and Tejada, Cesar Augusto and Hallal, Pedro C. and Ferrario, Alessandra and Schmidt, Maria
  • The European pharmaceutical market and policies - outlook for the future. Kanavos, Panos and Vandoros, Sotiris and Irwin, Rachel and Nicod, Elena and Casson, Margaret
  • European pharmaceutical policy and implications for current member States and pre-accession countries. Kanavos, Panos
  • Evaluation of health care reform options. Kanavos, Panos and Mossialos, Elias
  • Financial flows to global health partnerships. Kanavos, Panos and Holmes, P. R.
  • Financing pharmaceuticals in transition. Kanavos, Panos
  • From vision to reality:the EU's pharmaceutical reforms and the path to improved access. Main, Caitlin and Schafer, Cathrin and Kanavos, Panos picture_as_pdf
  • HCC patient voices survey. Gill, J. L. and Baiceanu, A. and Clark, P. and Langford, A. and Latiff, J. and Wilson, A. and Yang, P-M. and Yoshida, E. and Kanavos, Panos
  • HPR85 Opinions on sustainable healthcare financing options for funding new medical technologies in Asean-6. Gill, Jennifer L and Chávez, Danitza and Main, Caitlin and Miracolo, Aurelio and Kanavos, Panos
  • HTA in Central and Eastern Europe: current status, challenges and opportunities. Sorenson, Corinna and Kanavos, Panos and Karamalis, M.
  • HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe:building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach. Kanavos, Panos and Alcaraz, OA and Chávez, Danitza and Colaci, C and Haig, Madeleine and Argento, F and Main, Caitlin and Alfie, Verónica and Mills, Mackenzie and Pichon-Riviere, DA and Augustovski, F
  • HTA201 A quantitative assessment of the economic decision drivers outlined in HTA outcomes through stratification and sentiment analysis:evidence from Canada, England, Scotland, and Sweden. Eaves, K. and Lin, R. and Mills, M. and Kanavos, Panos
  • HTA255 First-in-class drugs in HTA:blunder or bliss? Politopoulou, Konstantina and Mills, Mackenzie and Kanavos, Panos
  • Health and drug sector reform in Turkey: caveats and opportunities. Kanavos, Panos and Ustel, I. and Tatar, M. and Costa-i-Font, Joan
  • Health care after the Great Recession: financing options for sustainable and high-quality health systems. Kanavos, Panos and Wouters, Olivier J.
  • Health care inequities in north India: role of public sector in universalizing health care. Prinja, Shankar and Kanavos, Panos and Kumar, Rajesh
  • Health care reform in Turkey: a dynamic path in the wake of political consensus. Tatar, Mehtap and Kanavos, Panos
  • Health economics: an evolving paradigm. Maynard, Alan and Kanavos, Panos
  • Health related quality of life aspects not captured by EQ-5D-5L: results from the IMPrESS (International MultiPlE SclerosiS) study. Mossman, Jean and Efthymiadou, Olina and Tinelli, Michela and Kanavos, Panos
  • Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products:evidence from nine OECD countries. Mills, Mackenzie and Kanavos, Panos picture_as_pdf
  • Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Kanavos, Panos and Ferrario, Alessandra and Vandoros, Sotiris and Anderson, Gerard F.
  • How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe. Fontrier, Anna-Maria and Kamphuis, Bregtje W. and Kanavos, Panos picture_as_pdf
  • How can we improve secondary prevention of cardiovascular disease? Gill, Jennifer and Miracolo, Aurelio and Politopoulou, Konstantina and Jayawardana, Sahan and Carter, Alex and Apostolou, Efstratios A. and Kanavos, Panos picture_as_pdf
  • How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Mills, Mackenzie and Kanavos, Panos picture_as_pdf
  • How should functionally equivalent drugs be reimbursed? A retrospective analysis of reimbursement for Epoetin-[alpha] and Darbepoetin-[alpha] in 2001-2003 and the cost implications for CMS. Kanavos, Panos and Saka, Ömer R
  • How should functionally equivalent drugs be reimbursed?: A retrospective analysis of reimbursement for epoetin alfa and Darbepoetin alfa in 2001–3 and the cost implications for CMS. Kanavos, Panos and Saka, O
  • ICER value framework 2020 update:recommendations on the aggregation of benefits and contextual considerations. Angelis, Aris and Kanavos, Panos and Phillips, Lawrence D. picture_as_pdf
  • The IMPrESS (International Multiple Sclerosis Study);socio-economic burden, health related quality of life andexperiences of multiple sclerosis patients in France. Kanavos, Panos and Tinelli, Michela and Efthymiadou, Olina and Mossman, Jean
  • The Impact of External Reference Pricing within and across Countries. Kanavos, Panos and Fontrier, Anna-Maria and Gill, Jennifer and Efthymiadou, Olina and Boekstein, Nicola
  • Impact of regulation of community pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Lluch, Maria and Kanavos, Panos
  • The Implementation of External Reference Pricing within and across Country Borders. Kanavos, Panos and Fontrier, Anna-Maria and Gill, Jennifer and Kyriopoulos, Dionysis and Boekstein, Nicola
  • Implications of financing systems. Kanavos, Panos
  • Importaciones paralelas de medicamentos: El caso de la Simvastaina en Alemania, Holanda y el Reino Unido. Costa-i-Font, Joan and Kanavos, Panos
  • Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Gill, Jennifer and Baiceanu, Andrei and Clark, Paul J and Langford, Andrew and Latiff, Julianah and Yang, Pei-Ming and Yoshida, Eric M and Kanavos, Panos picture_as_pdf
  • Insurance coverage and the heterogeneity of health and drug spending in the United States. Gemmill, Marin and Costa-i-Font, Joan and Kanavos, Panos
  • International impact of external reference pricing:should national policy makers care? Fontrier, Anna-Maria and Gill, Jennifer and Kanavos, Panos picture_as_pdf
  • Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Angelis, Aris and Tordrup, David and Kanavos, Panos
  • The LSE Summit: risk sharing and managed entry agreements. Ferrario, Alessandra and Kanavos, Panos
  • Large scale mergers and acquisitions in the pharmaceutical industry: 1 + 1 = 1? Angelis, Aris and Kanavos, Panos
  • Latin America healthcare system overview:a comparative analysis of fiscal space in healthcare. Kanavos, Panos and Parkin, Georgia Colville and Kamphuis, Bregtje and Gill, Jennifer
  • Launch sequencing of pharmaceuticals with multiple therapeutic indications:evidence from seven countries. Mills, Mackenzie and Michaeli, Daniel and Miracolo, Aurelio and Kanavos, Panos picture_as_pdf
  • MSR1 Estimating lifetime benefits of optimizing secondary preventive treatment for atherosclerotic cardiovascular disease. Gill, Jennifer L and Miracolo, Aurelio and Politopoulou, Konstantina and Jayawardana, Sahan and Apostolou, Efstratios A. and Carter, Alex and Kanavos, Panos
  • Managed entry agreements for pharmaceuticals: the European experience. Ferrario, Alessandra and Kanavos, Panos
  • Managing healthcare reform: evaluation of available options. Kanavos, Panos and Mossialos, Elias
  • Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. Berg Brigham, Karen and Darlington, Meryl and Wright, John S. F. and Lewison, Grant and Kanavos, Panos and Durand-Zaleski, Isabelle
  • Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States. Kanavos, Panos
  • Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector. Kanavos, Panos and Soumerai, Stephen B and Ross-Degnan, Dennis
  • Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Sorenson, Corinna and Kanavos, Panos
  • Medicines in parallel trade in the European Union: a gravity specification. Costa-i-Font, Joan and Kanavos, Panos
  • Moving towards better outcomes in Multiple Sclerosis by addressing policy change. Kanavos, Panos and Tinelli, Michela and Efthymiadou, Olina and Mossman, Jean
  • Multi-criteria decision analysis for health technology assessment:addressing methodological challenges to improve the state of the art. Oliveira, Mónica D. and Mataloto, Inês and Kanavos, Panos picture_as_pdf
  • Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Angelis, Aris and Kanavos, Panos
  • Multiple criteria decision analysis for HTA across four EU member states:piloting the Advance Value Framework. Angelis, Aris and Linch, Mark and Montibeller, Gilberto and Molina Lopez, Maria Teresa and Zawada, Anna and Orzel, Kinga and Arickx, Francis and Espin, Jaime and Kanavos, Panos picture_as_pdf
  • Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework. Kanavos, Panos and Angelis, Aris
  • Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. Angelis, Aris and Montibeller, Gilberto and Hochhauser, Daniel and Kanavos, Panos
  • National Institute for Health and Clinical Excellence (NICE). How does it work and what are the implications for the U.S? Sorenson, Corinna and Drummond, Michael and Kanavos, Panos and McGuire, Alistair
  • Navigating the digital health landscape for chronic disease management:a value assessment framework for patient-facing technologies. Haig, Madeleine and Main, C and Chavez, D and Kanavos, Panos
  • OP141 Patient relevant outcome measures as predictors of health care use in multiple sclerosis. Tinelli, Michela and Efthymiadou, Olina and Mossman, Jean and Kanavos, Panos
  • On improving accessibility of drugs for the poor. Kanavos, Panos and Lim, J Y and Pascual, C S
  • On improving the poor's access to affordable drugs. Kanavos, Panos and Lim, J Y and Pascual, C S
  • Orphan drug considerations in Health Technology Assessment ineight European countries. Tordrup, David and Tzouma, Victoria and Kanavos, Panos
  • Outstanding regulatory issues in the European Union pharmaceutical market. Kanavos, Panos and Mossialos, Elias
  • Overview of pharmaceutical pricing and reimbursement regulation. Kanavos, Panos
  • P36 Towards a collaborative value assessment framework for provider-facing digital health technologies used in chronic disease management:Findings and Implications. Main, Caitlin and Haig, Madeleine and Kanavos, Panos
  • PND27 – the Impress (International Multiple Sclerosis) study; results on the socio-economic burden, health related quality of life and experience of multiple sclerosis patients in France. Kanavos, Panos and Tinelli, Michela and Efthymiadou, O. and Visintin, E. and Grimaccia, Federico and Mossman, J.
  • PRM164 - reconsidering EQ-5D; quality of life domains that are important for Multiple Sclerosis patients. Mossman, J. and Efthymiadou, O. and Tinelli, Michela and Kanavos, Panos
  • PROMS as predictors of healthcare use in multiple sclerosis. Tinelli, Michela and Efthymiadou, Olina and Mossman, Jean and Kanavos, Panos
  • Parallel trade and pharmaceutical prices: a game-theoretic approach and empirical evidence from the European Union. Vandoros, Sotiris and Kanavos, Panos
  • Parallel trading in medicines: Europe’s experience and its implications for commercial drug importation in the United States. Kanavos, Panos and Gross, David and Taylor, David
  • Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Pringle, Edward and Kanavos, Panos
  • Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Prevost, Andrew T. and Simpson, Andrew R.H. and Kanavos, Panos
  • Pharmaceutical parallel trade in Europe: stakeholders and competition effects. Kanavos, Panos and Costa-i-Font, Joan
  • Pharmaceutical parallel trade: legal, policy, and economic issues. Kanavos, Panos and Wouters, Olivier J.
  • Pharmaceutical policies in Cyprus: a review of the current system and future options. Kanavos, Panos and Wouters, Olivier J.
  • Pharmaceutical policy in China. Kanavos, Panos and Mills, Mackenzie and Zhang, Anwen picture_as_pdf
  • Pharmaceutical pricing and reimbursement in Europe. Kanavos, Panos and Gemmill, Marin
  • Pharmaceutical regulation in Europe. Kanavos, Panos
  • Policy options for pharmaceutical research and development in the European Community. Mossialos, Elias and Kanavos, Panos and Abel-Smith, B.
  • Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey. Tordrup, David and Angelis, Aris and Kanavos, Panos
  • Prescription drug coverage among elderly and disabled Americans: can Medicare—Part D reduce inequities in access? Kanavos, Panos and Gemmill-Toyama, Marin
  • Pricing of in-patent pharmaceuticals in the Middle East and North Africa:is external reference pricing implemented optimally? Kanavos, Panos and Kamphuis, Bregtje and Fontrier, Anna-Maria and Parkin, Georgia Colville and Saleh, Shadi and Akhras, Kasey S. picture_as_pdf
  • Pricing pharmaceuticals: value based pricing in what sense? McGuire, Alistair and Raikou, Maria and Kanavos, Panos
  • Primary health care should play bigger role in treating chronic kidney disease. Wouters, Olivier J. and Kanavos, Panos
  • Product differentiation, competition and regulation of new drugs: the case of statins in four European countries. Kanavos, Panos and Costa-i-Font, Joan and McGuire, Alistair
  • Progress in addressing the growing diabetes epidemic is lagging behind due to poor control of the disease. Ferrario, Alessandra and Kanavos, Panos
  • RWE in Europe Paper II: The use of Real World Evidence in the disease context. Gill, Jennifer and Kanavos, Panos and Albanell, Joan and Dank, Magdolna and Duncombe, Robert and Fink-Wagner, Antje and Hutton, John and Jahnz-Różyk, Karina and Kossler, Ingrid and Podrazilova, Katerina and Schramm, Wolfgang and Spandonaro, Federico and Thomas, Michael and Wartenberg, Markus
  • RWE in Europe Paper III: A Roadmap for RWE. Gill, Jennifer and Albanell, Joan and Avouac, Bernard and Berger, Karin and Boerlum Kristensen, Finn and Bucher, Heiner C. and Duncombe, Robert and Fink-Wagner, Antje-Henriette and Hutton, John and Jahnz-Różyk, Karina and Kossler, Ingrid and Podrazilova, Katerina and Spandonaro, Federico and Thomas, Michael and Vaz-Carneiro, Antonio and Wartenberg, Markus and Kanavos, Panos
  • RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap. Gill, Jennifer and Kanavos, Panos and d'Angela, Daniela and Berger, Karin and Dank, Magdolna and Duncombe, Robert and Fink-Wagner, Antje and Hutton, John and Kossler, Ingrid and Podrazilova, Katerina and Thomas, Michael
  • Reconsidering EQ-5D; quality of life domains that are important for multiple sclerosis patients. Efthymiadou, Olina and Tinelli, Michela and Mossman, Jean and Kanavos, Panos
  • Reference pricing for drugs: is it compatible with US healthcare? Kanavos, Panos
  • Regulating pharmaceutical distribution and retail pharmacy in Europe. Kanavos, Panos and Tatar, D and Taylor, D
  • Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Angelis, Aris and Kanavos, Panos and Montibeller, Gilberto
  • Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? Tordrup, David and Mossman, Jean and Kanavos, Panos
  • Review of the Estonian pharmaceutical sector: towards the development of a national medicines policy. Kanavos, Panos and Vandoros, Sotiris and Habicht, Jarno and de Joncheere, Kees
  • Road traffic mortality and economic uncertainty:evidence from the United States. Kanavos, Panos and Vandoros, Sotiris picture_as_pdf
  • Scientific and social value judgments for orphan drugs in health technology assessment. Nicod, Elena and Kanavos, Panos
  • Senior citizens and the burden of prescription drug outlays: what lessons for the Medicare prescription drug benefit? Kanavos, Panos and Gemmill, M
  • Severe asthma care and treatment:indicators and data for performance management across ten countries. Kamphuis, Bregtje and Efthymiadou, Olina and Kanavos, Panos and Tzouma, Victoria picture_as_pdf
  • Short- and long-term effects of value-based pricingvs. external price referencing. Kanavos, Panos and Nicod, Elena and Espin, Jaime and van den Aardweg, Stacey
  • Sin taxes and their effect on consumption, revenue generation and health improvement:a systematic literature review in Latin America. Miracolo, Aurelio and Sophiea, Marisa and Mills, Mackenzie and Kanavos, Panos picture_as_pdf
  • Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey. Kanavos, Panos and Tinelli, Michela and Mossman, Jean
  • Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey. Tinelli, Michela and Kanavos, Panos and Mossman, Jean
  • Social economic costs, quality of life and experience in multiple sclerosis patients and their caregivers: the IMPrESS (International MultiPlE SclerosiS) survey. Tinelli, Michela and Kanavos, Panos and Mossman, J.
  • Social impact of MS – the family burden. Kanavos, Panos and Tinelli, Michela and Efthymiadou, Olina and Visintin, Erica and Grimaccia, Federico and Mossman, Jean
  • Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Angelis, Aris and Tordrup, David and Kanavos, Panos
  • Sustainable healthcare financing for SDG3 in ASEAN-6. Gill, Jennifer and Chávez, Danitza and Main, Caitlin and Miracolo, Aurelio and Fontrier, Anna-Maria and Kanavos, Panos picture_as_pdf
  • Symptomatic vitreomacular adhesion. Jackson, Timothy and Nicod, Elena and Simpson, Andrew and Angelis, Aris and Grimaccia, Federico and Kanavos, Panos
  • Tender Loving Care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. Bonser, Andrew and Kanavos, Panos and Taylor, David
  • Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium. Kanavos, Panos and Seeley, Elizabeth and Vandoros, Sotiris
  • Topic 1: financing medical devices in France and the UK. Sorenson, Corinna and Kanavos, Panos
  • Toward greater efficiency and equity in healthcare resource allocation: Dr Panos Kanavos to lead consortium in ADVANCE_HTA European Commission FP7 grant. Kanavos, Panos
  • Towards better outcomes in autism by addressing policy change. Efthymiadou, Olina and Kamphuis, Bregtje and Gill, Jennifer and Haig, Madeleine and Kanavos, Panos picture_as_pdf
  • Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS). Kanavos, Panos and Tinelli, Michela and Efthymiadou, Olina and Visintin, Erica and Grimaccia, Federico and Mossman, Jean
  • Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS). Kanavos, Panos and Tinelli, Michela and Efthymiadou, Olina and Visintin, Erica and Grimaccia, Federico and Mossman, Jean
  • Towards evidence-based decisions in health care: a prospective assessment of training needs in health economics and management in the European Union. Kanavos, Panos
  • Transatlantic Trade and Investment Partnership: international trade law, health systems and public health. Khan, Usman and Pallot, Robert and Taylor, David and Kanavos, Panos
  • Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Wouters, Olivier J. and Kanavos, Panos
  • Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them: an international survey of clinicians. Efthymiadou, Olina and Kamphuis, Bregtje and Kanavos, Panos and Tzouma, Victoria picture_as_pdf
  • Türkiye'de ilaç geri ödeme politikası. Kanavos, Panos and Ustel, Ismail and Costa-Font, Joan
  • Understanding the role of governance in the pharmaceutical sector: from laboratory to patient. Cylus, Jonathan and Wouters, Olivier J. and Kanavos, Panos
  • Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines:a retrospective analysis. Kanavos, Panos and Visintin, Erica and Angelis, Aris picture_as_pdf
  • User charges in health care: evidence of effect on service utilization & equity from north India. Prinja, Shankar and Aggarwal, Arun Kumar and Kumar, Rajesh and Kanavos, Panos
  • Using IMPrESS to guide policy change in multiple sclerosis. Tinelli, Michela and Kanavos, Panos and Efthymiadou, Olina and Visintin, Erica and Grimaccia, Federico and Mossman, Jean
  • Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases? López-Bastida, J. and Ramos-Goñi, J. M. and Aranda-Reneo, I. and Trapero-Bertran, M. and Kanavos, Panos and Rodriguez Martin, B.
  • Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. López-Bastida, Julio and Ramos-Goñi, Juan Manuel and Aranda-Reneo, Isaac and Taruscio, Domenica and Magrelli, Armando and Kanavos, Panos picture_as_pdf
  • Validation of the Russian federal prescribing database and evaluation of policy outcomes. Kanavos, Panos and Vandoros, Sotiris
  • Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis:HTA evidence from seven OECD countries. Visintin, Erica and Tinelli, Michela and Kanavos, Panos
  • Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. Angelis, Aris and Kanavos, Panos
  • Variations in external reference pricing implementation:does it matter for public policy? Gill, Jennifer and Fontrier, Anna-Maria and Kyriopoulos, Dionysis and Kanavos, Panos description
  • Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Prevost, Toby and Simpson, Andrew and Kanavos, Panos
  • What is wrong with orphan drug policies?: suggestions for ways forward. Kanavos, Panos and Nicod, Elena
  • An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines:evidence from 35 countries. Leon, Giovanny and Carbonel, Christophe and Rampuria, Aparajit and Singh Rajpoot, Ravindra and Joshi, Parth and Kanavos, Panos picture_as_pdf
  • The burden of colorectal cancer: prevention, treatment and quality of services. Kanavos, Panos and Schurer, Willemien
  • The burden of diabetes and options for reform:insights for the Greek health system. Haig, Madeleine and Therianos, Panagiotis and Miracolo, Aurelio and Satish, Kavyashree and Kolovou, Vasiliki and Kanavos, Panos picture_as_pdf
  • A comparison of generic drug prices in seven European countries: a methodological analysis. Wouters, Olivier J. and Kanavos, Panos
  • The dynamics of colorectal cancer management in 17 countries. Kanavos, Panos and Schurer, Willemien
  • The economic impact of pharmaceutical parallel trade in European union member states: a stakeholder analysis. Kanavos, Panos and Costa-i-Font, Joan and Merkur, S. and Gemmill, M.
  • The economics of blood: gift of life or a commodity? Kanavos, Panos and Yfantopoulos, J. and Politis, C. and Vandoros, C.
  • The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Von der Schulenburg, Fritz and Vandoros, Sotiris and Kanavos, Panos
  • The generics paradox revisited: empirical evidence from regulated markets. Vandoros, Sotiris and Kanavos, Panos
  • The impact of health technology assessments: an international comparison. Kanavos, Panos and Nicod, Elena and van den Aardweg, Stacey and Pomedli, Stephen
  • The impact of non-treatment of schizophrenia in OECD countries: a literature review. Tinelli, Michela and Kanavos, Panos and Winkler, Petr and Knapp, Martin and Höschl, Cyril and Pompili, Maurizio
  • The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Wouters, Olivier J. and Sandberg, Dale M. and Pillay, Anban and Kanavos, Panos picture_as_pdf
  • The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Ferrario, Alessandra and Arāja, Diāna and Bochenek, Tomasz and Čatić, Tarik and Dankó, Dávid and Dimitrova, Maria and Fürst, Jurij and Greičiūtė-Kuprijanov, Ieva and Hoxha, Iris and Jakupi, Arianit and Laidmäe, Erki and Löblová, Olga and Mardare, Ileana and Markovic-Pekovic, Vanda and Meshkov, Dmitry and Novakovic, Tanja and Petrova, Guenka and Pomorski, Maciej and Tomek, Dominik and Voncina, Luka and Haycox, Alan and Kanavos, Panos and Vella Bonanno, Patricia and Godman, Brian
  • An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Ferrario, Alessandra and Sautenkova, Nina and Bezverhni, Zinaida and Seicas, Rita and Habicht, Jarno and Kanavos, Panos and Safta, Vladimir
  • The increasing use of economic evaluation of pharmaceuticals, part 1: guidelines for economic evaluation and their role in health policy. Trueman, P. and Kanavos, Panos and Wallace, M.
  • The increasing use of economic evaluation of pharmaceuticals, part 2: 'the fourth hurdle': what does it mean for drug development? Trueman, P. and Kanavos, Panos and Wallace, M.
  • The patient pathway in ATTR-CM in Greece and how to improve it:a multidisciplinary perspective. Apostolou, Efstratios A. and Fontrier, Anna Maria and Efthimiadis, Georgios K. and Kastritis, Efstathios and Parissis, John and Kanavos, Panos picture_as_pdf
  • The pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices. Kanavos, Panos and Schurer, Willemien and Vogler, Sabine
  • The promise of population health management in England:from theory to implementation. Main, Caitlin and Haig, Madeleine and Kanavos, Panos picture_as_pdf
  • The rising burden of cancer in the developing world. Kanavos, Panos
  • The role of funding and policies on innovation in cancer drug development. Kanavos, Panos and Sullivan, R. and Lewison, G. and Schurer, W. and Eckhouse, S. and Vlachopioti, Z.
  • The role of virtual health care and the pharmaceutical sector in improving population health. Kamphuis, Bregtje and Gill, Jennifer and Vogelzang, Michelle and Haig, Madeleine and Kanavos, Panos
  • The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings. Kanavos, Panos
  • A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop. Al-Omar, Hussain Abdulrahman and Almuhsin, Asma Abdulaziz and Almudaiyan, Lolwa Hamad and Al-Najjar, Amal Hassan and Abu Esba, Laila Carolina and Almodaimegh, Hind and Altawil, Esraa S. and Yousef, Consuela Cheriece and Khan, Mansoor Ahmed and Alyahya, Khalid and Alamre, Jehan and Maraiki, Fatma and Espin, Jaime and Tarricone, Rosanna and Kanavos, Panos picture_as_pdf
  • A structured methodology for essential medicines lists and health emergency stockpiles:experience with the Emergency Medicines Buffer Stock in the United Kingdom. Angelis, Aris and Montibeller, Gilberto Neto and Kanavos, Panos picture_as_pdf
  • A systematic review of value criteria for next-generation sequencing/ comprehensive genomic profiling to inform value framework development. Augustovski, Federico and Colaci, Carla and Mills, Mackenzie and Chávez, Danitza and Argento, Fernando and Alfie, Verónica and Pichon Riviere, Andrés and Kanavos, Panos and Alcaraz, Andrea picture_as_pdf
  • The use of Real World Evidence in the European context: An analysis of key expert opinion. Gill, Jennifer and Kanavos, Panos and Avouac, Bernard and Duncombe, Robert and Hutton, John and Jahnz-Różyk, Karina and Schramm, Wolfgang and Spandonaro, Federico and Thomas, Michael
  • A value framework to assess patient-facing digital health technologies that aim to improve chronic disease management:a Delphi approach. Haig, Madeleine and Main, Caitlin and Chávez, Danitza and Kanavos, Panos picture_as_pdf
  • The value of early diagnosis and treatment in Parkinson's disease: a literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease. Tinelli, Michela and Kanavos, Panos and Grimaccia, Federico